Chalfont, St. Giles, UK 11/28/17—GE Healthcare Life Sciences’ BioProcess business has acquired Puridify for an undisclosed amount. Puridify’s FibroSelect nano-scale single-use purification technology is designed to improve process development and small-scale manufacturing, with faster mass transfer, scalability and ease of use. Puridify has 17 employees based in the UK. GE stated that the technology complements bead resins and chromatography membranes for separations. “The technology that Puridify has been developing gives GE access to exciting technology that could give considerable improvements for some customers in their purification step. The early feedback from collaborators has been positive,” said Jan Makela, general manager, BioProcess, GE Healthcare Life Sciences.

Utilizing a 3D matrix structure of cellulosic nanofibers, FibroSelect addresses the drawbacks with current bioprocess separation techniques, according to the company, providing a fast flow rate and increase flexibility resulting in higher productivity. GE joins the list of bioprocess tool companies adding single-use technologies for downstream separations, including Pall (see IBO 4/15/15) and MilliporeSigma (see IBO 8/31/17).